In vivoBrainstem Imaging in Alzheimer's Disease: Potential for Biomarker Development

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


The dearth of effective treatments for Alzheimer's disease (AD) is one of the largest public health issues worldwide, costing hundreds of billions of dollars per year. From a therapeutic standpoint, research efforts to date have met with strikingly little clinical success. One major issue is that trials begin after substantial pathological change has occurred, and it is increasingly clear that the most effective treatment regimens will need to be administered earlier in the disease process. In order to identify individuals within the long preclinical phase of AD who are likely to progress to dementia, improvements are required in biomarker development. One potential area of research that might prove fruitful in this regard is the in vivo detection of brainstem pathology. The brainstem is known to undergo pathological changes very early and progressively in AD. With an updated and harmonized AD research framework, and emerging advances in neuroimaging technology, the potential to leverage knowledge of brainstem pathology into biomarkers for AD will be discussed.

Original languageEnglish
Article number266
JournalFrontiers in Aging Neuroscience
Issue numberSEP
StatePublished - Sep 11 2018

Bibliographical note

Publisher Copyright:
© 2007 - 2018 Frontiers Media S.A. All Rights Reserved.


  • Alzheimer's disease
  • Biomarker
  • Brainstem
  • Imaging
  • In vivo
  • Locus coeruleus
  • Neuroimaging
  • Raphe nucleus

ASJC Scopus subject areas

  • Aging
  • Cognitive Neuroscience


Dive into the research topics of 'In vivoBrainstem Imaging in Alzheimer's Disease: Potential for Biomarker Development'. Together they form a unique fingerprint.

Cite this